Share Price, page-11458

The price to sales ratio of a company is just one of many tools used by investors to evaluate companies.Below are some calculations using this ratio that are relevant to Neuren and Acadia:
The price-to-sales ratio (Price/Sales or P/S) is calculated by taking a company's market capitalization and divide it by the company's total sales.The beauty of this ratio is its simplicity and the fact that it cannot be subject to accounting tricks like the P/E ratio.The ratio indicates at a point in time how much an investor is prepared to pay per dollar of sales for a particular stock.The ratio per entity is readily available the on most finance stock sites.
* Neuren has a current P/S ratio of 8.75 and compares well to the ASX as a whole [2.15] and more importantly to its sector @ 4.70.TLX has a P/S ratio of 12.32.[refer CMC Markets]
*Acadia P/S ratio is currently 2.91.This number was at 7.5 at 30/6/2023.The Teva figure currently is 1.15 and Pfizer sits at 2.93 [refer Yahoo Finance]

At least the above calculations show something different to when comparing the market capitalizations of the relevant two companies-one of which is expensive and profitable v the other which is cheaper and yet to record a profit.
I hope this post is of interest.
Kens